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Introduction
The unprecedented demand for hospital services during the
SARS-CoV-2 (COVID-19) pandemic has dramatically reduced
the capability for dealing with non-acute health needs, includ-
ing cancer care [1, 2]. To alleviate burden on health care sys-
tems, including imaging and laboratory services, curtailment of
non-COVID-19-related research activity has been necessary
[3]. Measures that reduce hospital visits have been adopted to
limit risk of infection and death, which is critical in a cancer
population whose age and immunocompromised status in-
creases their risk [4]. Imaging, however, requires hospital visits
and close contact with staff and equipment; both are sources of
disease transmission. Equipment used to image COVID-19
cases may retain virus on its surface for days [5, 6] unless
disinfected. The need for social distancing and for disinfecting
equipment substantially slows imaging workflow and reduces
throughput. This article discusses the specific impact of pan-
demics such as SARS-CoV-2 on imaging in oncological trials.
Patients currently on trials
Imaging trial activities that demand quality assurance, techni-
cal and biological validation and PET pharmacokinetic studies
are all considered non-essential during a pandemic and are
largely discontinued. For ongoing therapeutic trials requiring
imaging, a pandemic poses significant challenges. Unlike oth-
er adaptations to trial workflow through remote study visits,
delayed site-monitoring visits and direct delivery of investiga-
tional products to patients who are self-isolating [7], imaging
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cannot be performed remotely. International pharmaceutical
regulatory bodies have not stipulated specific modifications
regarding the use of imaging; they merely recommend
assessing risks of physical visits, doing study-related assess-
ments at different sites and providing patients with personal
protective equipment (PPE) to ensure their safety [8]. As the
risk of infection with SARS-CoV-2 to cancer patients attend-
ing hospital might be doubled [9], and with many patients
fearful of attending hospital even for clinical care, the risk of
losing imaging data from oncological trials is high. Dedicated
scanning facilities restricted to patients tested negative for
infection would provide a potential solution.
The imposed changes on the availability of imaging for
trial activity, including the availability of radionuclides and
radiopharmaceuticals, and the risks of infection with hospital
attendancemean that principal investigators and sponsors may
re-evaluate imaging frequency within existing trial protocols.
However, a reduction in imaging frequency may miss mile-
stones that indicate progression or harmful side effects and
continuation on an ineffective or toxic drug regimen.
Postponing the acquisition of imaging-based trial endpoints
also jeopardises timely recording of progression events, which
can distort estimates of treatment effect and lead to erroneous
trial conclusions (e.g., efficacious intervention but negative
trial). In fact, it may be argued that imaging frequency should
be increased to monitor complications (pneumonitis, pulmo-
nary embolism), posed by the additional risks of COVID-19
in pyrexial trial patients [10].
A major challenge also remains in image interpretation.
Differentiation of pandemic-specific (COVID-19) pulmonary
changes from other pneumonias requires definitive molecular
testing [10]. When a patient drops out of a trial due to infec-
tion, there are implications for ongoing patient management
and for trial endpoints.
New patient recruitment
The abrupt discontinuation of research activities due to a pan-
demic such as COVID-19 also has had a substantial impact on
new recruitment of patients into oncological trials (Fig. 1).
Risk of secondary infection in immunocompromised cancer
patients and diversion of radiology, pathology and pharmacy
services to cope with the pandemic has meant that many spon-
sors have deferred new patient recruitment. Moreover, the
reduction in non-urgent hospital visits has reduced the number
of new cancer diagnoses [1] and the opportunity to evaluate
the eligibility and suitability of potential new recruits, based
on imaging. Capacity to perform image-guided biopsies
which are crucial in determining trial eligibility also can be
limited by radiologist, facilities and PPE shortages.
Baseline imaging findings often affect inclusion of new
patients, by increasing the need for additional imaging to eval-
uate incidental findings and by requiring complementary
modalities to ensure inclusion criteria are met. In the presence
of unexpectedCOVID-19-specific pneumonia on baseline im-
aging, managing the patient and potentially recruiting them to
newly developed COVID-19 trials has taken priority over on-
cology trials. Treatments such as chimeric antigen receptor
(CAR) T-cells, often done in a trial setting, must be avoided
if there is active SARS-CoV-2 infection. As restrictions ease,
and hospital visits recommence, options to increase recruit-
ment to oncological trials include remote visits and video-
based communication to inform potential candidates about
trials and maintain productivity [11]. However, baseline im-
aging and biopsies to establish eligibility will require hospital
visits, which may well be still considered low priority. Delays
in recruiting patients risk their oncological progression and
subsequent ineligibility. Trials that require multiple image-
guided biopsies whilst on treatment may be particularly diffi-
cult to re-start because of capacity issues. Initiation of new
projects (“site initiation visit”) is deferred until travel restric-
tions are lifted and visits to hospitals by non-essential persons
are restored.
Patient perspective
Participation in clinical trials is profoundly dictated by a pa-
tient’s perception of the potential risk-benefit to themselves
[12], and imaging may be perceived as a burden [13]. Many
imaging-based clinical trials, however, merely incorporate re-
search imaging as an additional component to routine imaging
or utilise images acquired for clinical care. The impact of a
pandemic in these cases therefore reflects that on non-essential
clinical imaging services [14]. In therapeutic trials with mul-
tiple imaging studies at intervals, patients may be hesitant to
participate because of concerns, fuelled by official regulations
and messages, over frequent hospital visits and reluctance to
use public transport without adequate PPE. For patients living
in communities or institutions, imposed quarantine periods on
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Fig. 1 Total accrual to EORTC therapeutic studies in the four months
prior and 4 months during COVID-19 pandemic, compared to the total
recruitment over the corresponding months 1 year before
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After a pandemic, oncology and imaging departments need
to jointly rebuild patient confidence in trial visits. Where
available and practical, dedicated “infection-cold” care areas
with separate patient pathways and scanner units could be
designated and this communicated to trial patients.
Contacting patients prior to the imaging visit, enquiring about
possible symptoms, should reassure them that safety proce-
dures are enforced and that imaging examinations can be re-
scheduled where needed. Additional body temperature checks
at the entrance of scanning facilities, supply of surgical masks,
provision for hand sanitisation, social distancing measures in
waiting areas, signage and one-way systems through imaging
departments [14, 15] all inspire confidence in patients attend-
ing for trial imaging studies.
Waiting times for scan results are a known source of patient
anxiety [16]. The pandemic has forced an upsurge in telemed-
icine communication pathways, so exploiting these to main-
tain patient motivation for trial imaging attendance could be
used to advantage. Moreover, as imaging studies may poten-
tially reveal incidental findings suggestive of pandemic-
related (COVID-19) infection, information from structured
and timely review of imaging findings communicated early
to patients within trials would further incentivise them to at-
tend imaging sessions. Patients should be made aware of these
advantages in monitoring and care that support their trial
participation.
Organisational issues—institution and department
policies
Trial-related imaging, currently delayed due to any “lock-
down” strategy adopted in most countries and pandemic-
related priorities, is delayed further by post-pandemic imaging
capacity limits. Social distancing measures are likely to re-
main imposed after lifting a lockdown. Once routine practice
is resumed, a certain period of re-adjustment is needed to cope
concurrently with new and legacy workload in already tight
healthcare systems. Imaging within clinical trials is often low
priority, particularly in smaller centres where spare imaging
capacity is non-existent. In trials where imaging is considered
optional, or where imaging is the sole research question, im-
age data collection might suffer.
Workflow within imaging departments is likely to be ad-
versely affected by the need for using PPE, particularly for
procedures such as ultrasound and image-guided biopsies.
This has implications for time, preparation and waiting room
space. Examinations will take longer and, where protocols
require adaptation, their complexity will increase. It is essen-
tial that the workflow through an imaging department is
optimised for the clinical workload to effectively accommo-
date imaging for trials.
The increase in reporting workload for nuclear medicine
physicians and radiologists when non-urgent clinical work
re-starts may well also impact the timely scoring and reporting
of trial data. The consequences of pandemic-induced stress on
imaging staff in a post-pandemic era should not be
underestimated [17], especially when they have been re-
deployed to the “front line”. Where incidental findings of
pandemic-related (COVID-19) infection are noted in trial pa-
tients, rapid communication channels to site principal investi-
gators should be established.
COVID-19 pneumonia as an ‘incidental’ finding
Many oncological patients undergo chest CT to assess their
primary tumour or to rule out lung metastasis. The lungs also
are partially included on non-chest dedicated CTs, e.g. H&N,
abdomen, CT for SPECT/CT or on daily radiotherapy cone
beam CT scans [18]. Where abnormality is noted, a full-chest
CT is warranted. Therefore, patients on oncological trials will
inevitably have incidentally detected findings that could be
attributable to COVID-19 pneumonia. A 9% incidence was
reported from a nuclear medicine department performing rou-
tine [18F]-FDG-PET/CT and SPECT/CT in oncology patients
during the peak of the pandemic [19]. Patterns of COVID-19
pneumonias with these imaging modalities are now emerging
[20] and where detected should prompt an immediate alert and
SARS-COV-2 testing. The need for supplementary dedicated
chest CT in (a)symptomatic patients would follow similar
principles regardless of the pandemic. However, the require-
ment for radiologists to decide whether or not to mention
COVID-19 specifically, rather than simply “viral” pneumonia,
is debatable. Expert consensus statements for reporting chest
CT findings of COVID-19 have been published [21, 22].
From a trial perspective, it remains essential only to distin-
guish infection/inflammation from oncological progression.
From an imaging perspective, how these pneumonias are re-
corded influences the assessment of the specific impact of the
COVID-19 pandemic on trial outcome. From a public health
perspective, these patients need to be isolated.
Opportunities
For the reasons discussed, patients might miss imaging follow-
up visits during oncology trials, which will create subpopula-
tions of patients with strictly trial-governed versus limited im-
aging follow-up. This offers the opportunity for a critical review
of the real need for and frequency of imaging. While imaging
follow-up through cancer treatment is a pillar of oncology trials
to monitor treatment efficacy and detect recurrences, it is
recognised that recommendations in terms of frequency of
follow-up are often empirical/arbitrary, particularly if there is
no evidence of disease. Previous work showed that intensifying
follow-up of cancer patients did not improve overall survival
nor influence health-related quality of life [23, 24]. This period
of reduced imaging availability could be an opportunity for
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(re)discovering the true value of imaging, rather than merely
exploiting it for reassurance and surveillance.
Future perspective
Based on prior experience with SARS andMERS, COVID-19
is unlikely to be the last pandemic or major global crisis that
impacts imaging for patient care or in clinical trials.
Accordingly, there are important lessons to be learned from
the shortcomings and experience of the current situation.With
imaging so integral to clinical trials in oncology, it is crucial
that cancer research is not held back by failure to deliver
timely imaging, compliant to protocol. Pathways where imag-
ing studies can be directed to local sites with spare capacity,
semi-automated readouts to reduce staff pressure and facilities
that exclude potentially infectious patients need to be within
institutional policies, to pre-empt and minimise disruption to
imaging within research trials in future pandemics [25].
Ongoing adaptations could be the creation of safer pathways,
dedicated to vulnerable patients within imaging units and hos-
pitals and minimisation of potential exposure to pathogens
through grouped clinical, laboratory and imaging visits.
Flexible imaging protocols, adaptable strategies and response
measures [26–28] to account for differences in national
healthcare organisation and in line with the national severity
of the crisis should enable the imaging community to deal
with future events with minimal disruption and maximal effi-
ciency so as to deliver time-dependent and time-critical stud-
ies within clinical trials.
Conclusion
Re-instatement of normal imaging workload after a pandemic
[29] requires administrative support and planning adaptation,
with extended scanning hours and appointments through a
workflow that retains social distancing practices and incorpo-
rates additional hygiene processes. A reduced throughput for
clinical imaging studies will inevitably impact trial-related
imaging and image-guided biopsies, resulting in a slowdown
of trial activity. To counteract this, the lessons learned regard-
ing smarter use of imaging within trials and improved com-
munications systems between physicians and imagers, doctors
and patients should be exploited to improve the delivery of
imaging within oncological trials in future crises.
Total accrual to EORTC therapeutic studies in the 4 months
prior and 4months duringCOVID-19 pandemic compared to the
total recruitment over the corresponding months 1 year before.
Funding information This publication was supported by a donation from
“Kom op tegen Kanker” from Belgium. Christophe M. Deroose is a
Senior Clinical Investigator at Research Foundation—Flanders (FWO).
No writing assistance was obtained for this manuscript.
Compliance with ethical standards
Disclaimer The funding sources had no active role in collection of the
data, writing and final approval of the manuscript.
Conflict of interest ChristopheM. Deroose reports fees for consulting or
advisory roles with Ipsen, Novartis, Terumo and Advanced Accelerator
Applications; participation in speakers’ bureaus with Terumo and
Advanced Accelerator Applications and travel, accommodations or ex-
penses with General Electric and Terumo.
Caroline Caramella reports honoraria from Pfizer, BMS,MSD, Astra-
Zeneca and Roche.
Laure Fournier reports research support from Philips, ArianaPharma,
Evolucare and Invectys; honoraria or consulting fees from Novartis,
Janssen and Sanofi and speaker fees from Novartis, Bayer, Janssen,
Sanofi, Pfizer and GE Healthcare.
Marion Smits reports honoraria paid to the institution for trial review
by Parexel Ltd. and for lecturing by GE Healthcare.
Laurence Collette, Daniela E. Oprea-Lager, Wolfgang G. Kunz,
Frédéric Lecouvet, Luc Bidaut, Joost J.C. Verhoeff, Egesta Lopci,
Bertrand Tombal, Lioe-Fee de Geus-Oei, Laure Fournier and Nandita
M. deSouza declare no conflicts of interest.
Studies with human participants or animals This article does not con-
tain any studies with human participants or animals performed by any of
the authors.
References
1. Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ,
van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses
during the COVID-19 epidemic in the Netherlands. Lancet Oncol.
2020. https://doi.org/10.1016/S1470-2045(20)30265-5.
2. van de Haar J, Hoes LR, Coles CE, SeamonK, Fröhling S, Jäger D,
et al. Caring for patients with cancer in the COVID-19 era. Nat
Med. 2020;26:665–71. https://doi.org/10.1038/s41591-020-0874-
8.
3. Gewin V. Safely conducting essential research in the face of
COVID-19. Nature. 2020;580:549–50.
4. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with
cancer appear more vulnerable to SARS-COV-2: a multi-center
study during the COVID-19 outbreak. Cancer Discov. 2020.
https://doi.org/10.1158/2159-8290.CD-20-0422.
5. Warnes SL, Little ZR, Keevil CW. Human coronavirus 229E re-
mains infectious on common touch surface materials. mBio.
2015;6:e01697–15.
6. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG,
Gamble A, Williamson BN, et al. Aerosol and surface stability of
SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med.
2020;382:1564–7.
7. Tan AC, Ashley DM, Khasraw M. Adapting to a pandemic -
conducting oncology trials during the SARS-CoV-2 pandemic.
Clin Cancer Res. 2020. https://doi.org/10.1158/1078-0432.CCR-
20-1364.
8. de Paula BHR, Araujo I, Bandeira L, Barreto N, Doherty GJ.
Recommendations from national regulatory agencies for ongoing
cancer trials during the COVID-19 pandemic. Lancet Oncol.
2020;21:624–7.
9. Yu J, OuyangW, Chua MLK, Xie C. SARS-CoV-2 transmission in
patients with cancer at a tertiary care hospital in Wuhan, China.
JAMAOncol. 2020. https://doi.org/10.1001/jamaoncol.2020.0980.
Eur J Nucl Med Mol Imaging
10. Yang W, Sirajuddin A, Zhang X, Liu G, Teng Z, Zhao S, et al. The
role of imaging in 2019 novel coronavirus pneumonia (COVID-19).
Eur Radiol. 2020. https://doi.org/10.1007/s00330-020-06827-4.
11. Vagal A, Reeder SB, Sodickson DK, Goh V, Bhujwalla ZM,
Krupinski EA. The impact of the COVID-19 pandemic on the
radiology research Enterprise: radiology scientific expert panel.
Radiology. 2020;201393. https://doi.org/10.1148/radiol.
2020201393.
12. Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial
enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105–14.
13. May K, Lee M, Jefford M, Ribeiro A, Macdonald A, Morgan V,
et al. Imaging in clinical trials: a patient-led questionnaire study to
assess impact of imaging regimes on patient participation. Res
Involv Engagem. 2020;6:15.
14. Mossa-Basha M, Meltzer CC, Kim DC, Tuite MJ, Kolli KP, Tan
BS. Radiology department preparedness for COVID-19: radiology
scientific expert panel. Radiology. 2020;200988. https://doi.org/10.
1148/radiol.2020200988.
15. Goh Y, Chua W, Lee JKT, Ang BWL, Liang CR, Tan CA, et al.
Operational strategies to prevent coronavirus disease 2019
(COVID-19) spread in radiology: experience from a Singapore ra-
diology department after severe acute respiratory syndrome. J Am
Coll Radiol JACR. 2020. https://doi.org/10.1016/j.jacr.2020.03.
027.
16. Ollivier L, Apiou F, Leclere J, Sevellec M, Asselain B, Bredart A,
et al. Patient experiences and preferences: development of practice
guidelines in a cancer imaging department. Cancer Imaging. 2009;9
Spec No A:S92–S97.
17. Giovagnoni A. Facing the COVID-19 emergency: we can and we
do. La Radiologia medica. 2020;125:337–8.
18. Youssef IDB, Flyer M, Thompson S, Huang A, Gallant F. Covert
Covid-19: CBCT lung changes in an asymptomatic patient receiv-
ing radiotherapy. Adv Radiat Oncol. 2020. https://www.astro.org/
ASTRO/media/ASTRO/Daily%20Practice/PDFs/COVID-
Youssef(ADRO).pdf.
19. Albano D, Bertagna F, Bertoli M, Bosio G, Lucchini S, Motta F,
et al. Incidental findings suggestive of COVID-19 in asymptomatic
patients undergoing nuclear medicine procedures in a high-
prevalence region. J Nucl Med. 2020;61:632–6.
20. Tulchinsky M, Fotos JS, Slonimsky E. Incidental CT Findings sus-
picious for Covid-19 associated pneumonia on nuclear medicine
exams: recognition and management plan. Clin Nucl Med 2020.
https://doi.org/10.1097/RLU.0000000000003100.
21. Simpson S, Kay FU, Abbara S, Bhalla S, Chung JH, Chung M,
et al. Radiological Society of North America Expert Consensus
Statement on Reporting Chest CT Findings Related to COVID-
19. Endorsed by the Society of Thoracic Radiology, the American
College of Radiology, and RSNA. J Thorac Imaging. 2020. https://
doi.org/10.1097/RTI.0000000000000524.
22. Prokop M, van Everdingen W, van Rees VT, Quarles van Ufford J,
Stoger L, Beenen L, et al. CO-RADS - a categorical CTassessment
scheme for patients with suspected COVID-19: definition and eval-
uation. Radiology. 2020:201473. https://doi.org/10.1148/radiol.
2020201473.
23. Benamore R, Shepherd FA, Leighl N, Pintilie M, Patel M, Feld R,
et al. Does intensive follow-up alter outcome in patients with ad-
vanced lung cancer? J Thorac Oncol. 2007;2:273–81 d.
24. Jeffery M, Hickey BE, Hider PN, See AM. Follow-up strategies for
patients treated for non-metastatic colorectal cancer. Cochrane
Database Syst Rev. 2016;11:CD002200.
25. Davenport MS, Bruno MA, Iyer RS, Johnson AM, Herrera R,
Nicola GN, et al. ACR statement on safe resumption of routine
radiology care during the COVID-19 pandemic. J Am Coll
Radiol. 2020. https://doi.org/10.1016/j.jacr.2020.05.001.
26. Paez D, Gnanasegaran G, Fanti S, Bomanji J, Hacker M, Sathekge
M, et al. COVID-19 pandemic: guidance for nuclear medicine de-
partments. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.
1007/s00259-020-04825-8.
27. Zhao Y, Xiang C, Wang S, Peng C, Zou Q, Hu J. Radiology de-
partment strategies to protect radiologic technologists against
COVID19: experience from Wuhan. Eur J Radiol. 2020;127:
108996.
28. Czernin J, Fanti S, Meyer PT, Allen-Auerbach M, Hacker M,
Sathekge M, et al. Nuclear medicine operations in the timeS of
COVID-19: strategies, precautions, and experiences. J Nucl Med.
2020;61:626–9 d.
29. Luker GBA. Transitioning to a new normal after COVID-19: pre-
paring to get back on track for cancer imaging. Radiol Imaging
Cancer. 2020. https://doi.org/10.1148/rycan.2020204011.
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Eur J Nucl Med Mol Imaging
View publication stats
